The Effectiveness of Perovskia abrotanoides Extract Topical Formulation on the Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial

Objective: Despite many attempts to treat leishmaniasis, new approaches are necessary to reduce the burden of disease. Perovskia abrotanoides (Brazambel) has shown significant effects against Leishmania parasites in some studies. This study aimed to investigate the effects of P. abrotanoides extract...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Research in Pharmacy Practice 2023-07, Vol.12 (3), p.104-109
Main Authors: Tayebi, Maryam Sadat, Poostiyan, Nazila, Dinani, Masoud Sadeghi, Ghassami, Erfaneh, Soltani, Rasool
Format: Article
Language:English
Subjects:
clinical trial
cutaneous leishmaniasis
leishmaniasis
Original
perovskia abrotanoides
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Despite many attempts to treat leishmaniasis, new approaches are necessary to reduce the burden of disease. Perovskia abrotanoides (Brazambel) has shown significant effects against Leishmania parasites in some studies. This study aimed to investigate the effects of P. abrotanoides extract topical formulation on cutaneous leishmaniasis. Methods: In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (n = 18) and control (n = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime®). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%– 75%), or treatment failure (reepithelialization
ISSN:2319-9644
2279-042X
DOI:10.4103/jrpp.jrpp_13_24